New discovery may lead to therapy for incurable blood cancer

February 23, 2004

A recent finding may lead to new treatments for multiple myeloma, an incurable cancer of immune cells called plasma cells that are present in the blood and bone marrow. The research, published in the February issue of Cancer Cell, reveals a frequent and common abnormal cellular event that occurs in about half of all myeloma cases and identifies an attractive target for therapeutic intervention.

A research team led by Dr. Louis M. Staudt from the National Cancer Institute in Bethesda, Maryland examined a cancer-causing gene, or oncogene, called c-maf and the interaction of myeloma cells with other types of cells within the bone marrow. Using a sophisticated genetic screening technique, the researchers found that c-maf was present and elevated in about half of all myeloma cases whereas it was absent from normal plasma cells. The researchers further demonstrated that c-maf increases the production of not only factors that directly promote tumor cell growth but also factors that promote tumor cell growth indirectly by increasing adhesion of pathological tumor cells to other types of cells within the bone marrow. Perhaps most significantly, inhibition of c-maf function in myeloma cells blocked tumor formation in mice.

The researchers conclude that c-maf is both functional and overabundant in close to one half of all myelomas and contributes to the pathology of the disease by stimulating both cell proliferation and attachment to structural elements within the bone marrow. According to Dr. Staudt, "Our results indicate that overproduction of c-maf is one of the most common abnormal events associated with myeloma. Further, our finding that inhibition of c-maf blocks myeloma proliferation and tumor formation makes c-maf an intriguing and exciting novel target for future therapies."
-end-
Elaine M. Hurt, Adrian Wiestner, Andreas Rosenwald, A.L. Shaffer, Elias Campo, Tom Grogan, P. Leif Bergsagel, W. Michael Kuehl, and Louis M. Staudt: "Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma"

Published in Cancer Cell, February 2004, Volume 5, Number 2, pages 191-200.

Cell Press

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.